



## Mechanisms of Cell Death in Cancer Cells: A New Therapeutic Opportunity

Guest Editors:

**Dr. Adrian-Bogdan Țigu**

Department of Translational  
Medicine, MEDFUTURE—Institute  
of Medical Research and Life  
Sciences, "Iuliu Hațieganu"  
University of Medicine and  
Pharmacy, 400337 Cluj-Napoca,  
Romania

**Dr. Ciprian Tomuleasa**

Department of Hematology,  
Institute of Oncology "Ion  
Chiricuta", University of Medicine  
and Pharmacy "Iuliu Hațieganu",  
400012 Cluj-Napoca, Romania

Deadline for manuscript  
submissions:

**closed (31 March 2024)**

### Message from the Guest Editors

We are pleased to announce a new Special Issue in *Biomedicines* focused on the “Mechanisms of Cell Death in Cancer Cells: A New Therapeutic Opportunity”.

Cancer initiation and progression are sustained by a series of broad alterations in molecular pathways as a result of genetic error, external stimuli, etc. One such pathway with crucial importance to human health is the mechanism of cell death. As such, multiple cancer-associated alterations have often been proven to modulate or even abrogate cell death. Therefore, targeting the molecular pathways which are directly or indirectly involved in the mechanism of cell death represents a potential therapeutic strategy for the development of efficient antitumor molecules. The Special Issue is meant to highlight outstanding research involving novel and previously described and repositioned therapeutic compounds which can target the mechanism of cell death in both solid and hematological malignancies.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)